Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03241186 · ClinicalTrials.gov registry record · Phase 2
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
A Phase 2 study of Mucosal Melanoma, sponsored by Robert R. McWilliams, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 7
- Study locations
NCT03241186: Active Phase 2 study of Mucosal Melanoma, sponsored by Robert R. McWilliams, MD.
NCT03241186 is a Phase 2 study of Mucosal Melanoma that is active but no longer recruiting, run by Robert R. McWilliams, MD. The registered enrollment target is 36 participants, below the 151-participant average among 12 other Mucosal Melanoma trials with a reported enrollment target (76% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03241186, a Phase 2 study of Mucosal Melanoma, is active but no longer recruiting, sponsored by Robert R. McWilliams, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a single arm phase II clinical trial of Ipilimumab and Nivolumab in patients with resected mucosal melanoma. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) will be administered Day 1 of a 21-day cycle in Cycles 1-4 and then nivolumab 480 mg will be administered Day 1 of a 28-day cycle for Cycles 5-15 (maximum of 15) or until disease recurrence or intolerance before completion of 15 cycles.
Primary Outcome
Date the patient receives the first dose of study medication to the date of documentation of first disease recurrence or death due to any cause.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
Study Locations (7)
Minnesota
- University of Minnesota - Minneapolis
- Mayo Clinic Rochester - Rochester
Florida
- Mayo Clinic- Florida - Jacksonville
Iowa
- University of Iowa Hospital and Clinics - Iowa City
Nebraska
- Nebraska Cancer Specialists - Omaha
Oregon
- Providence Portland Medical Center - Portland
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-09-12 |
| Est. Completion | 2023-09 |
| Phase | Phase 2 |
What the registry record for NCT03241186 still lists
NCT03241186 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 151-participant average among 12 other Mucosal Melanoma trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Mucosal Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03241186 lists 7 locations in 6 states (Minnesota, Florida, Iowa).
Frequently Asked Questions
What is clinical trial NCT03241186 about?
NCT03241186 is a clinical study titled "Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma". This is a single arm phase II clinical trial of Ipilimumab and Nivolumab in patients with resected mucosal melanoma. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) will be administered Day 1 of a 21-day cycle in Cycles 1-4 and then nivolumab 480 mg will be administered Day 1 of a 28-day cycle for Cycl...
What is the current status of trial NCT03241186?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2017-09-12. Estimated completion is 2023-09.
What conditions does trial NCT03241186 study?
This clinical trial studies the following conditions: Mucosal Melanoma.
What interventions are being tested in trial NCT03241186?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT03241186?
This trial is sponsored by Robert R. McWilliams, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03241186 being conducted?
This trial has 7 study locations across Florida, Iowa, Minnesota, Nebraska, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mucosal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03241186's enrollment target sits among peer trials
36 9th of 12 higher than 4 of 12 other Mucosal Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mucosal Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
RECRUITING · Phase 2
-
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
-
Dinaciclib in Treating Patients With Stage IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI